Tanzania launches genomic sequencing to reshape precision medicine and health security

For years, a Tanzanian patient suspected of carrying a rare genetic mutation or facing an unusual cancer had few options: wait months for results, pay thousands of dollars, and send biological samples across the ocean to laboratories in Europe or North America. The samples would travel. The analysis would happen elsewhere. The answers would come back slowly, if at all. That arrangement is ending.

At the 14th Scientific Conference of Muhimbili University of Health and Allied Sciences in Dar es Salaam, the university unveiled next-generation sequencing services—a laboratory capability that allows Tanzania to analyze genetic material within its own borders. Dr Siana Nkya, who heads the Muhas Genetics Laboratory, framed the moment as a threshold. "We are not simply launching a laboratory service," she said. "We are opening the door to a new era of genomic medicine in our country and in the region."

The timing matters. Tanzania is simultaneously pursuing Universal Health Coverage, bracing for declining international health aid, and confronting a disease landscape that has grown more complex. The country carries a heavy burden of infectious diseases like tuberculosis and malaria while facing a rising tide of non-communicable diseases—cancers, diabetes, hypertension—that often require genetic insight to treat effectively. Genomics offers a tool to understand why diseases develop, why the same medicine works differently in different people, and how infections mutate and spread. The technology has become essential globally for cancer diagnosis, rare disease detection, tracking antimicrobial resistance, and detecting outbreaks before they spiral.

The Covid-19 pandemic illustrated the advantage starkly. Countries that could sequence viral samples rapidly identified new variants, mapped transmission chains, and adjusted public health strategy in real time. Those dependent on sending samples abroad fell behind. Africa's disease control authorities took note and began prioritizing genomic capacity across the continent. For Tanzania, the ability to test and analyze samples locally means biological data stays within the country, strengthening what experts call health sovereignty—the capacity to understand and respond to threats without waiting for external partners.

Dr Nkya emphasized a second benefit: precision medicine. Traditional healthcare applies standard protocols. A patient with certain symptoms receives a standard drug. Precision medicine inverts that logic. By reading a patient's genetic code, clinicians can predict how that specific person will respond to a specific drug, allowing treatment tailored to individual biology rather than population averages. This matters most acutely in cancer, where genetic mutations determine which therapies will work. It matters too for the growing number of Tanzanians living with multiple conditions simultaneously—a diabetic patient who also has hypertension and malaria, or a cancer patient requiring genetic testing alongside conventional care.

Yet the conference surfaced a harder truth: technology alone does not deliver universal healthcare. Prof Nathanael Sirili, a Muhas researcher, challenged the room to think beyond the laboratory. "It is time for shifting our mindsets from single disease logic to integrated care," he said. "We should not see malaria in a patient, but we should see a patient with malaria." His observation reflected decades of fragmentation in African health systems, where HIV programs, tuberculosis programs, and malaria programs often operated as separate silos with their own financing, data systems, and staff. That architecture made sense when those diseases dominated. It makes less sense now, when patients arrive with overlapping conditions and when health systems must function as integrated networks connecting community clinics, district hospitals, referral centers, and specialized facilities.

Financing emerged as the central constraint. International health assistance is becoming unpredictable, forcing Tanzania and other African countries to increase domestic investment. During the conference week, Tanzania signed a five-year health partnership with the United States committing $1.3 billion in American support and $1.8 billion in Tanzanian resources. Yet the WHO African Region's progress toward Universal Health Coverage has slowed. The region's service coverage index stood at 44 in 2021, far below the global average of 68. Out-of-pocket spending continues to push households into financial hardship. Prof Sirili stressed that the changing landscape demands ruthless focus on efficiency and value. "Domestic priorities have to come first, and value for money becomes more important."

Tanzania has already invested in laboratory networks, surveillance systems, and digital platforms like GoTHoMIS, installed in nearly all public health facilities. Genomics could amplify those efforts by supporting local development of diagnostics, strengthening antimicrobial resistance monitoring, and improving disease surveillance. But the real test, Prof Sirili argued, lies in implementation science—asking what works, for whom, at what cost, and under what conditions. The question that will ultimately determine whether Tanzania's genomic ambitions translate into real progress toward Universal Health Coverage is not whether the technology works. It is whether the health system can be reformed to use it.